Subtle abnormalities in kidney function—even within the range considered normal—may help identify people at risk of ...

Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

Subtle abnormalities in kidney function – even within the range considered normal – may help identify people at risk of ...

Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). This is an ASCO Meeting ...

Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...

Suresh Ramalingam, MD, FACP, FASCO, a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, is the executive director of the Winship Cancer Institute ...

Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...

The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...

Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. Background: Insulin and insulin-like growth factors are key regulators of normal metabolism and ...